Literature DB >> 18024410

Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia.

Andrica C H de Vries, Ronald W Stam, Christian P Kratz, Martin Zenker, Charlotte M Niemeyer, Marry M van den Heuvel-Eibrink.   

Abstract

Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative/myelodysplastic disorder associated with mutations in the Ras-Raf-MEK-ERK-signaling pathway. B-Raf plays a central role in this pathway. In 65 screened JMML patients we identified no BRAF mutations and we conclude that this gene is unlikely to play a role in the pathogenesis of JMML.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024410     DOI: 10.3324/haematol.11493

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  3 in total

1.  Molecular basis of juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; C Michael Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

Review 2.  Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.

Authors:  Christian Flotho
Journal:  Epigenetics       Date:  2019-03-08       Impact factor: 4.528

Review 3.  Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Authors:  Nao Yoshida; Sayoko Doisaki; Seiji Kojima
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.